Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial

Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial

Background: The radiochemotherapy regimen concomitantly employing temozolomide (TMZ) chemotherapy and radiotherapy (RT) 4 weeks after surgery, followed by 6 cycles of TMZ is a common treatment for glioblastoma (GBM). However, its median overall survival (OS) is only 14.6 months. This study was to ex...

Full description

Bibliographic Details
Main Authors: Ying Mao, Yu Yao, Li-Wei Zhang, Yi-Cheng Lu, Zhong-Ping Chen, Jian-Min Zhang, Song-Tao Qi, Chao You, Ren-Zhi Wang, Shu-Yuan Yang, Xiang Zhang, Ji-Sheng Wang, Ju-Xiang Chen, Qun-Ying Yang, Hong Shen, Zhi-Yong Li, Xiang Wang, Wen-Bin Ma, Xue-Jun Yang, Hai-Ning Zhen, Liang-Fu Zhou
Format: Article
Language:English
Published: Wolters Kluwer 2015-01-01
Series:Chinese Medical Journal
Subjects:
Chemoradiotherapy; Chemotherapy; Glioblastoma; Malignant Glioma; Temozolomide
Online Access:http://www.cmj.org/article.asp?issn=0366-6999;year=2015;volume=128;issue=20;spage=2751;epage=2758;aulast=Mao

Internet

http://www.cmj.org/article.asp?issn=0366-6999;year=2015;volume=128;issue=20;spage=2751;epage=2758;aulast=Mao

Similar Items